CD40LG and atherosclerosis: Genetic deficiency or antibody-mediated inhibition of CD40L is highly effective in reducing atherosclerosis, even in established disease conditions, by generating plaques that are rich in collagen and contain a limited amount of immune cells resembling the murine equivalent of a stable, clinically safe, plaque13–16.